M&A Deal Summary

Cambrex Acquires Cambrex Drug Product- Business Unit

On July 23, 2018, Cambrex acquired healthcare services company Cambrex Drug Product- Business Unit from SK Capital Partners for 425M USD

Acquisition Highlights
  • This is Cambrex’s 1st transaction in the Healthcare Services sector.
  • This is Cambrex’s largest (disclosed) transaction.
  • This is Cambrex’s 2nd transaction in the United States.
  • This is Cambrex’s 1st transaction in New Jersey.
Investment Fate
  • Cambrex Drug Product- Business Unit was divested to a consortium of strategic buyers in 2023.

M&A Deal Summary
Date 2018-07-23
Target Cambrex Drug Product- Business Unit
Sector Healthcare Services
Buyer(s) Cambrex
Sellers(s) SK Capital Partners
Deal Type Add-on Acquisition
Deal Value 425M USD
Advisor(s) Wells Fargo Securities
Mizuho Securities Co., Ltd. (Financial)
Morgan Lewis (Legal)

Target

Cambrex Drug Product- Business Unit

Whippany, New Jersey, United States
Cambrex Drug Product's Business Unit is a technology-focused contract manufacturing business with differentiated applications and capabilities in solid, semi-solid and liquid dosage forms, with a particular focus on controlled substances. Cambrex Drug Product's Business Unit was established in 2006 and is based in Whippany, New Jersey.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cambrex

East Rutherford, New Jersey, United States
Category Company
Founded 1981
Sector Life Science
Employees1,228
Revenue 534M USD (2017)
DESCRIPTION

Cambrex is a life sciences company that provides products, services, and technologies to accelerate the development and commercialization of small molecule therapeutics. Cambrex was formed in 1981 and is headquartered in East Rutherford, New Jersey.

DEAL STATS #
Overall 4 of 7
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 3 of 6
State (New Jersey) 1 of 1
Country (United States) 2 of 4
Year (2018) 1 of 2
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-09-26 PharmaCore

High Point, North Carolina, United States

PharmaCore, Inc. is a provider of small molecule drug discovery, development and manufacturing for pharmaceutical and biotechnology companies.

Buy $25M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-20 Avista Pharma Solutions

Lafayette, Colorado, United States

Avista Pharma Solutions is a contract development, manufacturing, and testing organization that understands advance products through every stage of development. With over 200,000 square feet of laboratory and manufacturing space in the U.S. and U.K., Avista offers a broad suite of scientifically differentiated services ranging from early-stage discovery, API and Drug Product development and cGMP manufacturing to stand-alone analytical and microbiology testing support.

Buy $252M

Seller(S) 1

SELLER

SK Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2007
PE ASSETS 4.9B USD
Size Large
Type Sector Agnostic
DESCRIPTION

SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.

DEAL STATS #
Overall 4 of 14
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 2 of 7
State (New Jersey) 1 of 1
Country (United States) 4 of 9
Year (2018) 2 of 3
Size (of disclosed) 4 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-06-01 Addivant

Danbury, Connecticut, United States

Addivant is a provider of a comprehensive portfolio of additives including antioxidants, antiozonants, inhibitors, polymer modifiers and UV stabilizers used by customers to improve the production and performance properties of polymers, plastics and rubbers. Addivant is headquartered in Connecticut and maintains a global footprint with 11 plants on five continents.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-20 AEB

Brescia, Italy

AEB is a provider of biotechnology solutions and process enablers for the food and beverage sector, particularly for the oenology market. AEB offers a wide range of products, allowing users to take advantage of the most innovative wine processing and treatment techniques. The result of advanced scientific and technical research, AEB products make use of unique formulations, answering in a targeted way any problem and need concerning the entire winemaking process. AEB was founded in 1963 and is based in Brescia, Italy.

Sell -
Mergr

Product

Company

Legal